Prognostic significance of igf-1 signaling pathway in patients with advanced non-small cell lung cancer.

Doctoral Dissertation uoadl:2886408 257 Read counter

Unit:
Τομέας Κλινικοεργαστηριακός
Library of the School of Health Sciences
Deposit date:
2019-11-27
Year:
2019
Author:
Kotsantis Ioannis
Dissertation committee:
Δημήτριος Πεκτασίδης, Ομότιμος καθηγητής, Ιατρική, ΕΚΠΑ
Γεώργιος Δημητριάδης, Καθηγητής, Ιατρική, ΕΚΠΑ
Ελένη Γκόγκα, Καθηγήτρια, Ιατρική, ΕΚΠΑ
Αμάντα Ψυρρή, Αναπληρώτρια καθηγήτρια, Ιατρική, ΕΚΠΑ
Βάια Λαμπαδιάρη, Αναπληρώτρια καθηγήτρια, Ιατρική, ΕΚΠΑ
Στυλιανός Λουκίδης, Αναπληρωτής καθηγητής, Ιατρική, ΕΚΠΑ
Σταυρούλα Γιαννούλη, Επίκουρη καθηγήτρια, Ιατρική, ΕΚΠΑ
Original Title:
Διερεύνηση του μοριακού μονοπατιού και της κλινικής συσχέτισης του αυξητικού παράγοντα της ινσουλίνης τύπου ένα (1) σε ασθενείς με προχωρημένο μη μικροκυτταρικό καρκίνο πνεύμονα (ΜΜΚΠ).
Languages:
Greek
Translated title:
Prognostic significance of igf-1 signaling pathway in patients with advanced non-small cell lung cancer.
Summary:
Background: Insulin-like growth factor 1(IGF-1) signaling pathway has been suggested as an important oncogenic mediator in various malignancies, including lung cancer. In this study, we aimed to evaluate serum levels of IGF-1, IGF-2 and IGF-Binding Protein 3 (IGF-BP3) before and after chemotherapy or chemoradiotherapy treatment in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) and their potential correlation with response to therapy and patient survival.
Methods: Seventy-three patients with stage III/IV NSCLC were included in the study. Expression of IGF1, IGF2, and IGFBP3 was evaluated in peripheral blood samples in two separate time points, at baseline and 3 months post treatment. Analysis and quantification of circulating levels of IGF-1, IGF-2, IGF-BP3 were performed by total ELISA technique. IGF-1/IGF-BP3 ratio is considered an indicator of IGF-1 bioavailability.
Results: In univariate analysis, the median value of IGF-1 after treatment (130.80 vs 98.00 ng/ml, p=0.087), and the median ratio of IGF-1/IGF-BP3 (0.01044 vs 0.00678, p=0.056) were higher in responders. Further analysis of the variation of each biomarker before and after treatment showed that the median value of IGF-1 was decreased after treatment in the total population (125.82 from 133.4 ng/ml, p=0.087), albeit no difference was found between subgroups. In addition, the median value of IGF-1/IGF-BP3 ratio was found to be lower after treatment in the total population (0.01006 from 0.01252, p=0.011). Importantly, the post-treatment value of the ratio was significantly reduced in responders (0.01044 from 0.01255, p=0.02). No correlation was found between variation in biomarker values, patient OS and PFS.
Conclusions: In a cohort of patients with stage III/IV NSCLC treated with chemotherapy or chemoradiotherapy, reduction of IGF-1/IGF-BP3 ratio, which is an indicator of IGF-1 bioavailability, was statistically significant in patients that responded to treatment. If validated in larger cohorts, our results support the use of IGF-1/IGFBP3 as a predictive tool for response to chemotherapy in NSCLC.
Main subject category:
Health Sciences
Keywords:
Igf-1, Igf-2, Igf-bp3, Non-small lung cancer, Chemotherapy
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
127
Number of pages:
127
Kotsantis Ioannis Phd.pdf (3 MB) Open in new window